- Trials with a EudraCT protocol (52)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
52 result(s) found for: Cholestyramine.
Displaying page 1 of 3.
EudraCT Number: 2004-001054-84 | Sponsor Protocol Number: 2004/W/GI/02 | Start Date*: 2005-02-16 |
Sponsor Name:NHS Lothian- University Hospitals Division | ||
Full Title: A comparison of the efficacy of dietary hydroxypropylcellulose and questran as therapeutic agents in bile acid induced diarrhoea | ||
Medical condition: these patients will have bile acid induced diarrhoea identified by an increased serum 7a-OH-cholestenone. and will have a history of one of 1. ileal resection 2. idiopathic bile acid diarrhoea.3. ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004419-32 | Sponsor Protocol Number: PMS-2018-002 | Start Date*: 2019-10-03 | ||||||||||||||||
Sponsor Name:Pharmascience Inc. | ||||||||||||||||||
Full Title: A Phase IIa, Proof of Concept, Randomized, Double-Blind, Dose-Finding, Cross-Over Study of the Efficacy, Safety and Tolerability of a New Enteric-Coated Cholestyramine Capsule in Adult Short Bowel ... | ||||||||||||||||||
Medical condition: Bile-acid induced diarrhea in adult patients with Short Bowel Syndrome (SBS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002466-22 | Sponsor Protocol Number: 990758 | Start Date*: 2015-12-23 |
Sponsor Name:Amgen Inc | ||
Full Title: A Randomized, Multi-center, Blinded, Placebo-controlled Study With an Openlabel Run-in Period to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daily, Single, Subcutaneous Injections of r-... | ||
Medical condition: Juvenile Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-023347-14 | Sponsor Protocol Number: 2010-10 | Start Date*: 2011-03-02 | |||||||||||
Sponsor Name:Gastroenterology CHC Liege | |||||||||||||
Full Title: Treatment of Crohn’s disease-associated refractory diarrhoea with octreotide LAR An open pilot study | |||||||||||||
Medical condition: Crohn Disease refractory diarrhoea | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004070-42 | Sponsor Protocol Number: A4250PBCpruritus | Start Date*: 2014-12-09 |
Sponsor Name:Sahlgrenska Academy | ||
Full Title: An Exploratory, Phase IIa Cross-Over Study to Demonstrate the Efficacy and Safety of A4250 in Patients with Primary Biliary Cirrhosis and Cholestatic Pruritus | ||
Medical condition: Primary biliary cirrhosis complicated by cholestatic pruritus. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-001114-17 | Sponsor Protocol Number: WA19923 | Start Date*: 2007-12-12 |
Sponsor Name:F. Hoffmann-La Roche Limited | ||
Full Title: A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to seve... | ||
Medical condition: Rheumatoid Arthritis (RA) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: Removed from public view |
EudraCT Number: 2004-003741-40 | Sponsor Protocol Number: WA17822 | Start Date*: 2004-11-26 |
Sponsor Name:F. Hoffmann La-Roche AG | ||
Full Title: A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moder... | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) SK (Completed) HU (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003493-27 | Sponsor Protocol Number: CQAL964B2201 | Start Date*: 2014-04-08 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable dos... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004892-21 | Sponsor Protocol Number: IP-004 | Start Date*: 2008-04-08 |
Sponsor Name:IMMUPHARMA SA | ||
Full Title: Estudio Fase IIb, Multicéntrico, Aleatorizado, Doble-Ciego, Controlado con Placebo de Búsqueda de dosis, para Evaluar Eficacia, Seguridad y Tolerabilidad de Dos Dosis Subcutáneas de IPP-201101 Más ... | ||
Medical condition: Lupus Eritematoso Sistémico (LES) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) BG (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002132-26 | Sponsor Protocol Number: WA18230 | Start Date*: 2008-02-19 |
Sponsor Name:F. Hoffmann-La Roche Limited | ||
Full Title: A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moder... | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001138-33 | Sponsor Protocol Number: WA17824 | Start Date*: 2005-07-14 | |||||||||||
Sponsor Name:F. Hoffmann La-Roche AG | |||||||||||||
Full Title: A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate (MTX) monotherapy, in patients with active rheumatoid arthritis. | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) NO (Completed) SI (Completed) DK (Completed) PT (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000050-38 | Sponsor Protocol Number: CAIN457F2342 | Start Date*: 2015-07-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of st... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) IE (Completed) HU (Completed) NL (Completed) ES (Completed) DE (Completed) IT (Completed) AT (Completed) LV (Completed) DK (Completed) CZ (Completed) FI (Completed) EE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002748-10 | Sponsor Protocol Number: CC-10004-PSA-014 | Start Date*: 2019-02-26 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects with Psoriatic Arthritis | |||||||||||||
Medical condition: Psoriatic arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) AT (Completed) DK (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005324-16 | Sponsor Protocol Number: LPS13539 | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis | |||||||||||||
Medical condition: multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001590-25 | Sponsor Protocol Number: CC-10004-PSA-006 | Start Date*: 2013-10-03 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) MONOTHERAPY IN SUBJECTS WITH ACTIVE PSORIATI... | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003330-32 | Sponsor Protocol Number: OSCO-P2201 | Start Date*: 2019-07-19 | |||||||||||
Sponsor Name:Oscotec Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite ... | |||||||||||||
Medical condition: Rheumatoid Arthritis Despite Treatment With Conventional Therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001153-23 | Sponsor Protocol Number: CAIN457I2401 | Start Date*: 2022-12-29 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial... | |||||||||||||
Medical condition: Non-radiographic axial spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005687-22 | Sponsor Protocol Number: CVAY736A2302 | Start Date*: 2022-06-13 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2) | |||||||||||||
Medical condition: Active Sjögren’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) BG (Trial now transitioned) IS (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000884-25 | Sponsor Protocol Number: WA18062 | Start Date*: 2005-06-14 |
Sponsor Name:F. Hoffmann-La Roche AG | ||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in ... | ||
Medical condition: Rheumatoid Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) IS (Completed) SE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010163-16 | Sponsor Protocol Number: 08/0285 | Start Date*: 2009-06-05 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease | ||||||||||||||||||
Medical condition: Active Crohn's disease affecting the ileum | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
